HomeCompareCARA vs DGRO

CARA vs DGRO: Dividend Comparison 2026

CARA yields 37.59% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CARA wins by $171.6K in total portfolio value
10 years
CARA
CARA
● Live price
37.59%
Share price
$5.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$203.2K
Annual income
$32,602.95
Full CARA calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — CARA vs DGRO

📍 CARA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCARADGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CARA + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CARA pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CARA
Annual income on $10K today (after 15% tax)
$3,195.49/yr
After 10yr DRIP, annual income (after tax)
$27,712.51/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, CARA beats the other by $27,508.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CARA + DGRO for your $10,000?

CARA: 50%DGRO: 50%
100% DGRO50/50100% CARA
Portfolio after 10yr
$117.4K
Annual income
$16,421.45/yr
Blended yield
13.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CARA right now

CARA
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$14.50
+172.6% upside vs current
Range: $1.00 — $30.00
Altman Z
-4.0
Piotroski
1/9
DGRO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CARA buys
0
DGRO buys
0
No recent congressional trades found for CARA or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCARADGRO
Forward yield37.59%2.13%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$203.2K$31.6K
Annual income after 10y$32,602.95$239.96
Total dividends collected$150.0K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CARA vs DGRO ($10,000, DRIP)

YearCARA PortfolioCARA Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$14,459$3,759.40$11,293$213.22+$3.2KCARA
2$20,552$5,080.25$12,730$217.32+$7.8KCARA
3$28,739$6,748.40$14,326$221.10+$14.4KCARA
4$39,570$8,819.34$16,098$224.56+$23.5KCARA
5$53,689$11,348.75$18,064$227.74+$35.6KCARA
6$71,837$14,390.67$20,246$230.65+$51.6KCARA
7$94,862$17,995.60$22,666$233.30+$72.2KCARA
8$123,711$22,208.66$25,349$235.73+$98.4KCARA
9$159,438$27,067.93$28,325$237.94+$131.1KCARA
10$203,202$32,602.95$31,624$239.96+$171.6KCARA

CARA vs DGRO: Complete Analysis 2026

CARAStock

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Full CARA Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this CARA vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CARA vs SCHDCARA vs JEPICARA vs OCARA vs KOCARA vs MAINCARA vs VIGCARA vs NOBLCARA vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.